References
not show increment of blasts; the patient also reduced his transfusion requirement (1 uRBC/every 10 days).
JAK2 V617F mutation analysis, when allele-specific PCR method [7] [8] [9] [10] became available, was retrospectively performed on genomic DNA sample obtained at diagnosis. The mutation was present in samples obtained at diagnosis and just before transplantation. The absence of the mutation was assessed on PB sample from the donor. Quantitative PCR of JAK2 V617F was not available either at diagnosis or before transplantation. JAK2 V617F mutation analysis was then reassessed on day þ 14, þ 20, þ 60 and þ 80 post-transplantation on bone marrow. No mutation was present leading to apparent JAK2 V617F eradication by allogeneic PBSCT as reported in Figure 1a . Chimerism analysis was also performed using short tandem repeat analysis at the same time intervals of JAK2 analysis, before and after SCT, showing 100% donor chimerism with no traces of DNA recipient (Figure 1b) . We could assess, thus, that JAK2 V617F mutation in this patient has apparently been eradicated by a non-myeloablative conditioning regimen followed by transplantation.
Standard-dose conditioning regimens followed by allogeneic transplantation are associated with a relatively high transplantrelated mortality in MMM. Introduction of RIC regimens has substantially reduced treatment-related mortality, expanding the access of fragile patients with MMM and achieving a 1-year survival rate of 90%.
11 Although the optimal conditioning regimen is currently unknown, our observation indicates that JAK2 V617F mutation can be eradicated shortly after RIC regimen and SCT. Molecular monitoring of treatment response in MMM is applicable to JAK2 V617F-positive cases and major molecular response could be defined as the absence of the mutation in samples of previously positive cases; however, whether eradication of mutation reflects also MMM disease resolution or a mere return to a pre-JAK2 V617F state is still unknown.
The downregulation of asparagine synthetase expression can increase the sensitivity of cells resistant to L-asparaginase L-asparaginase is a critical component of the combination chemotherapy for childhood acute lymphoblastic leukemia. It has been demonstrated to suppress the growth of leukemic cells by hydrolyzing asparagine to aspartic acid and ammonia, and causing the rapid depletion of asparagine in plasma. As a nonessential amino acid, asparagine could be synthesized from aspartate and glutamine by asparagine synthetase (AsnS) and is incorporated into amino-acid sequences of proteins.
1 Following administration of L-asparaginase, leukemic cells cannot compensate for the additional requirement of asparagine for their growth and development owing to the lack of sufficient AsnS activity. 2 The exact molecular events that cause cell death following L-asparaginase treatment keeps unknown. However, suppression of protein synthesis is an obvious potential target and it had been documented that L-asparaginase exposure could initiate apoptosis of the cells. 3 Aslanian et al. 4 overexpressed the AsnS protein in the Molt-4 cells using a Moloney mouse retrovirus system and induced the L-asparaginase resistance phenotype in the parental cells. Hutson et al. 5 demonstrated that the AsnS messsnger RNA (mRNA) level was in parallel to the AsnS protein level. Like the AsnS enzyme activity, the AsnS mRNA level was also correlated with the cellular resistance, which indicated that the AsnS mRNA level was an index of cells resistance to L-asparaginase. Therefore, our study is to investigate the possibility of reversing the L-asparaginase resistance and to further investigate the correlation of AsnS expression with Lasparaginase resistance by downregulating the AsnS mRNA level.
In a previous experiment, we had tested the AsnS mRNA and the 50% inhibiting concentration (IC 50 ) of eight cell lines including U937, Jurkat, HL-60, Namalwa, NB4, THP-1, K562 and Karpas299 by real-time quantitative polymerase chain reaction (RQ-PCR) and Cell Counting Kit-8 assay (CCK-8, Dojindo Corp., Japan), respectively. Among these cells, K562 (Human chronic myeloid leukemia cell line) and Karpas299 (Human anaplastic large-cell lymphoma cell line) displayed a natural resistance to L-asparaginase with the IC 50 values of both cells being greater than 100 U/ml, whereas the remaining six cells showed IC50 s less than 1 U/ml. Both of the two cells showed a significantly higher AsnS mRNA expression level and they were chosen for small hairpin RNA interference. To specifically downregulate the AsnS mRNA expression, vector pRNAT-H1.1/Neo/AsnS and pRNAT-H1.1/Neo/con were constructed by inserting two designed ds-DNA into the BamH1 and HindIII restriction site of the pRNAT-H1.1/Neo (GenScript Corp., NJ, USA). The inset of pRNAT-H1.1/Neo/AsnS was 5-GATCCGCTAAAGGTCTTGTTACATTTCAAGAGAATGTAACA AGACCTTTAGCTTTTTTA-3 and 5-AGCTTAAAAAAGCTAAAG GTCTTGTTACATTCTCTTGAAATGTAACAAGACCTTTAGCG-3, and the insert of pRNAT-H1.1/Neo/con was 5-GATCCTTCTCC GAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGA ATTTTTTA-3 and 5-AGCTTAAAAAATTCTCCGAACGTGTCAC GTTCTCTTGAAACGTGACACGTTCGGAGAAG-3. After screening viable cells by G418 sulfate and sorting for green fluorescent protein-positive cells by flow cytometry, we finally acquired four stable transfection cell lines: (a) K562/AsnS, (b) K562/Con, (c) Karpas299/AsnS and (d) Karpas299/Con. RQ-PCR assay confirmed that the abundance of AsnS mRNA of K562/AsnS and Karpas299/AsnS cells were significantly lower than that of K562/ Con and Karpas299/Con cells, respectively (Figure 1a) . By immunizing BALB/c mice with the full-length recombinant human AsnS protein (pET-22b þ expression system), we prepared a mouse monoclonal antibody specific to human AsnS. Western blot test showed that the AsnS protein levels of K562/ AsnS and Karpas299/AsnS were decreased correspondingly compared to that of controls (Figure 1b) . According to a method by Hutson et al. 5 and Sheng et al. 6 and modified by ourselves, a high-performance liquid chromatography assay detecting AsnS activity was established. The AsnS enzymatic activity was significantly decreased in stable RNA interference cell lines (7.48-and 14.66-fold downregulation for K562 and Karpas299, respectively, Figure 1c and Supplementary Figure 1) . Taken together, the data illustrated that AsnS mRNA, protein and enzymatic activity were specifically downregulated by RNA interference.
The biological characteristics of the AsnS interference cells showed considerable shift from the parental cells. The growth of stable RNA interference cells was highly retarded. In an assay for cell cycle distribution, more K562/AsnS and Karpas299/AsnS (Figure 2 ). The CCK-8 assay showed that the sensitivity of K562/AsnS and Karpas299/AsnS cell lines was increased to a level over 500-fold comparing to that of K562/Con and Karpas299/Con (Table 1) . Moreover, about 30% or more apoptotic cells were observed in Karpas299/AsnS and K562/AsnS cells that were exposed to 1 U/ml L-asparaginase for 48 h compared to control cells ( Figure 3 ). Our studies revealed that AsnS protein and its activity have been suppressed by specific interference of AsnS gene expression. Greco A et al. 7 demonstrated that temperature-sensitive AsnS mutants, when exposed to nonpermissive temperature, could not proceed through the cell cycle. In consistent with this, the AsnS mRNA interference cells displayed increased G0/G1 phase accumulation. After treating with L-asparaginase, AsnS mRNA interference cells showed more significant proliferation inhibition and apoptosis than the mock interference cells. Therefore, our results demonstrated that the L-asparaginase resistance of K562 and Karpas299 cells could be reversed through specifically downregulating the AsnS mRNA expression and the AsnS expression might be a potential target for dealing with L-asparaginase resistant leukemia.
